title: Anticoagulation: a GP primer on the new oral anticoagulants.
abstract: BACKGROUND
  The acceptability of warfarin has been limited by mandatory laboratory monitoring. A number of new orally active anticoagulants (NOACs), which can be used as alternatives to warfarin, are now available.
  
  
  OBJECTIVE
  We review the clinical indications and considerations associated with the use of the NOACs.
  
  
  CONCLUSIONS
  The NOACs currently approved in Australia are dabigatran, rivaroxaban and apixaban. Indications include thromboprophylaxis in non-valvular atrial fibrillation and following hip and knee replacement surgery. Rivaroxaban is also approved for treatment and secondary prevention of deep venous thrombosis (DVT) and pulmonary embolus (PE). The NOACs differ from warfarin in that they do not require laboratory monitoring. They need to be used cautiously in patients with renal impairment and are contraindicated in patients with renal failure. Bleeding may require blood product replacement aided by haematological advice and specialist investigations. Antidotes to the NOACS are undergoing clinical trials.
authors.affiliation: MBBS MMed (Clin Epi) PhD, FRACP, Professor, Director of Coronary Care and Coronary Interventions, Department of Cardiology, Concord Repatriation General Hospital, The University of Sydney, Concord, NSW.
authors.forename: David
authors.initials: D
authors.lastname: Brieger
mesh_terms: D000925:Anticoagulants / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D000991:Antithrombins / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000150:complications; D001562:Benzimidazoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001780:Blood Coagulation Tests; D000069604:Dabigatran; D016903:Drug Monitoring; D065427:Factor Xa Inhibitors; D058006:General Practice; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007668:Kidney / Q000378:metabolism; D009025:Morpholines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D011720:Pyrazoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D011728:Pyridones / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000069552:Rivaroxaban; D013876:Thiophenes / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D054556:Venous Thromboembolism / Q000517:prevention & control*; D014859:Warfarin / Q000494:pharmacology / Q000627:therapeutic use; D015091:beta-Alanine / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D065427:Factor Xa Inhibitors; D009025:Morpholines; D011720:Pyrazoles; D011728:Pyridones; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; D014859:Warfarin; D000069552:Rivaroxaban; D000069604:Dabigatran